Sai Parenterals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Sai Parenterals Ltd reported a 102.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were up by 69.9% QoQ and - - YoY.
• The net profit decreased 297.6% QoQ and - - YoY.
• The earnings per share (EPS) of Sai Parenterals Ltd stood at 4.02 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sai Parenterals Ltd is a company operating in the pharmaceutical industry, primarily focusing on the production and distribution of parenteral medicines and related healthcare products. Parenterals refer to products that are administered by injection through the skin or directly into the bloodstream, which is a key area in the pharmaceutical landscape. The company is known for its commitment to delivering high-quality parenteral solutions to meet the needs of healthcare providers and patients. While specific recent developments or strategic initiatives are not available in the provided data, Sai Parenterals Ltd continues to play a crucial role in its industry segment, leveraging its expertise in parenteral medicine production.

Revenue

In the fourth quarter of fiscal year 2026, Sai Parenterals Ltd recorded a total income of ₹200.81 crores. This represents a significant increase of 102.3% compared to the previous quarter, Q3FY26, where the total income was ₹99.28 crores. The year-over-year comparison with Q4FY25 is not applicable, as there is no revenue data available for that period. The substantial quarterly growth in revenue highlights a marked improvement in the company's income generation over the past quarter, although a direct year-over-year comparison cannot be made due to the lack of corresponding data from the previous year.

Profitability

In terms of profitability, Sai Parenterals Ltd achieved a profit before tax of ₹12.39 crores in Q4FY26, a notable turnaround from the previous quarter's loss of ₹11.62 crores. This quarter-over-quarter change indicates a positive shift in the company's financial performance. The tax expense for Q4FY26 was recorded as a credit of ₹0.76 crores, compared to a credit of ₹4.96 crores in Q3FY26, resulting in a profit after tax of ₹13.16 crores for the fourth quarter. This is a significant improvement from the previous quarter's loss after tax of ₹6.66 crores. Earnings per share for Q4FY26 stood at ₹4.02, providing an indication of the profitability on a per-share basis.

Operating Metrics

The financial data for Sai Parenterals Ltd indicates that total expenses for Q4FY26 amounted to ₹188.42 crores, compared to ₹110.91 crores in Q3FY26. This reflects an increase of 69.9% in expenses quarter-over-quarter. Despite the rise in expenses, the company's improved revenue performance contributed to achieving profitability in the fourth quarter. The absence of year-over-year data for Q4FY25 precludes a direct comparison of operating metrics with the same quarter from the previous year. Nonetheless, the current quarter's financial performance suggests a recovery from the previous quarter's operational challenges, as reflected in the profit margins and earnings per share metrics for Q4FY26.